Dr. Larissa Bornikova, MD

Dr. Bornikova practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Bornikova's NPI, 1356531453, was assigned on July 26, 2007. Dr. Bornikova graduated from University of New Mexico School of Medicine in 2003. Dr. Bornikova holds Massachusetts license 232037.

Dr. Bornikova's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Bornikova's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Bornikova is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Bornikova to 3 more hospitals, 3 medical groups and 1 community health center, each named with a free account. Dr. Bornikova's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bornikova practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bornikova's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bornikova is licensed in Massachusetts.

CMS data shows 530 Medicare services from Dr. Bornikova across 5 procedure codes in 2024, for 219 Medicare patients. Medicare paid $46,189 for them.

CMS counts 219 Medicare patients who saw Dr. Bornikova in 2024. The largest group is 65 to 74, with 82 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 23% are also on Medicaid. Their average risk score is 1.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bornikova's median patient age at 74, with 58% women.

In 2024, Dr. Bornikova wrote 198 Medicare Part D claims for 45 patients. 60% of them were for generic drugs. CMS names the drug for 120 of them, across 5 drugs with 11 or more claims each, at $43,429 in total drug cost. In 2023, CMS named 122 claims across 6 drugs.

Dr. Bornikova accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bornikova as offering telehealth.

Dmand AI links 7 papers to Dr. Bornikova, published from 2017 to 2022. The most frequent topics are Hemorrhage and Thrombosis. Dr. Bornikova's most frequent co-authors are Hanny Toban Al-Samkari, MD, Rachel P. Rosovsky, MD and Andrew M. Brunner, MD.

CMS Open Payments shows 23 general payments to Dr. Bornikova from 5 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 86% of the total. Sanofi and Genzyme US Companies paid the most, $24,788. It also lists 1 research payment totaling $100 in 2019.

Dr. Bornikova graduated from University of New Mexico School of Medicine in 2003.